I am a breastfeeding mother and i want to know if it is safe to use 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione? Is 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione safe for nursing mother and child? Does 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione extracts into breast milk? Does 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione has any long term or short term side effects on infants? Can 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione influence milk supply or can 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione decrease milk supply in lactating mothers?
- DrLact safety Score for 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione is 1 out of 8 which is considered Safe as per our analyses.
- A safety Score of 1 indicates that usage of 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione is mostly safe during lactation for breastfed baby.
- Our study of different scientific research also indicates that 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione does not cause any serious side effects in breastfeeding mothers.
- Most of scientific studies and research papers declaring usage of 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione safe in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
One case of nausea, vomiting and irritability has been described. However, 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione has been used as treatment of apnea on premature babies. It can enhance milk production by stimulating prolactin release.
An expert panel considers use of 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione to be acceptable during breastfeeding.[1] Maternal 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione use may occasionally cause stimulation and irritability and fretful sleep in infants. Newborn and especially preterm infants are most likely to be affected because of their slow elimination and low serum protein binding of 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione. There is no need to avoid 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione products; however, keep maternal serum concentrations in the lower part of the therapeutic range and monitor the infant for signs of 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione side effects. Infant serum 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione concentrations can help to determine if signs of agitation are due to 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione. Avoiding breastfeeding for an 2 hours after intravenous or 4 hours after an immediate-release oral 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione product can decrease the dose received by the breastfed infant. When 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione is given as an oral sustained-release product, timing of nursing with respect to the dose is of little or no benefit.
Irritability and fretful sleeping occurred in a 3-day-old breastfed infant on days of maternal aminophylline intake of 200 mg every 6 hours. These effects ceased with discontinuation and recurred on rechallenge over the next 9 months. These effects were probably caused by 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione in breastmilk. Another five infants reported in this paper showed no adverse reactions after maternal 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione ingestion.[3] Accumulation of 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione in infant serum appears most likely in neonates and premature infants because they eliminate 3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione slowly.[2][5]
Disclaimer:
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.